The goal of the initiative is to seek new solutions to unmet needs in supporting successful, long-term recovery from alcohol and opioid use disorders

OCTOBER 14 & 15, 2020

Deadline for applications was Friday, August 7, 2020


The Innovation Challenge will take place in October 2020 and will be open to Patient Entrepreneurs—those who have been affected by substance use disorders or co-morbidities as either a patient or support partner for a loved one.

Directional sign for honesty, courage, and acceptance
Patient Entrepreneurs with innovative companies in early stages of development will receive an invitation to pitch their solutions to an expert panel of judges comprised of healthcare industry, medical and patient leaders.

The winner will be awarded a $25,000 monetary grant. Additionally, competing finalists will be considered for possible partnerships/investments with/by Orexo.

The Lyfebulb–Orexo Innovation Challenge stems from the idea of the Lyfebulb Entrepreneur Circle, established in 2015, and features individuals who have created a product and a company based on issues encountered due to their personal experiences with a chronic illness (through their own diagnosis or that of a loved one).

The Finalists


Submissions should focus on digital health solutions, consumer products, telehealth, mobile health, health information technology, personalized care, and devices, sensors and wearables that support all facets of recovery.

The judging panel will assess the following:


  • What is the strategic basis for the identified problem/gap (e.g., research conducted)?
  • How is the problem/gap being specifically addressed?


  • Does the innovation have the potential to improve the lives of people affected by alcohol/opioid addiction?
  • How great of an impact (market impact and patient impact) will the innovation make and how will it be measured?


  • How is the product or service unique to the market?
  • What is the feasibility of development and implementation into the marketplace (e.g., funding, regulations, requirements for testing)?

The Judges


Applications for The Lyfebulb-Orexo Innovation Challenge: Solutions for Substance Use Disorders are now closed


Finalists are invited to present their innovative solutions that address an unmet need in substance use disorder recovery. One entrepreneur will be awarded the 2020 Lyfebulb-Orexo Innovation Award, including a $25,000 monetary grant to grow their company.

Applicants must be a Patient Entrepreneur (someone who has been affected by substance use disorder either as a patient or support partner for a loved one).

Applications closed Friday, August 7, 2020


Lyfebulb logoLyfebulb is a chronic disease-focused, patient empowerment platform that connects patients and industry to support user-driven innovation. Grounded with its strong foundation in diabetes, the company has expanded disease states covered into cancer, inflammatory bowel disease, multiple sclerosis, mental health, migraine, transplantation, and chronic cough.


Orexo logo

Orexo DTx is the digital health arm of Orexo AB, a pharmaceutical company that develops and commercializes improved pharmaceuticals and digital therapies. The company addresses unmet needs mainly within the growing space of addiction. Orexo DTx was created in Q4 of 2019 and currently has three products in the pipeline, vorvida® for alcohol misuse, deprexis® for depression, and OXD01 for opioid use disorder, all in partnership with the GAIA group.

Orexo DTx’s mission is to redefine treatment of addiction by offering clinically validated digital therapeutics to ensure more successful treatment for patients and cost-effective solutions for payers. The digital products will be commercialized by Orexo DTx worldwide, with the U.S. as the principal market, where Orexo also commercializes its lead product Zubsolv® (buprenorphine and naloxone) sublingual tablets (CIII) for treatment of opioid use disorder.

Orexo is listed on the Nasdaq Stockholm Mid Cap (ORX) and is available as ADRs on OTCQX (ORXOY) in the U.S. The company is headquartered in Uppsala, Sweden, where research and development activities are performed.